feed,title,long_url,short_url
Benzinga,Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success,https://benzinga.com/analyst-ratings/analyst-color/23/03/31243543/analyst-downgrades-gossamer-bio-as-mercks-sotatercept-might-overshadow-seralutinibs,https://da.gd/mNh1K
